(Q34606578)

3 August 2017

1 reference

title

Immunomodulation as a treatment strategy for genital herpes: review of the evidence (English)

1 reference

3 August 2017

1 reference

R L Miller

1

1 reference

3 August 2017

M A Tomai

series ordinal

2

1 reference

3 August 2017

C J Harrison

series ordinal

3

1 reference

3 August 2017

D I Bernstein

series ordinal

4

1 reference

3 August 2017

publication date

1 March 2002

1 reference

International Immunopharmacology

3 August 2017

published in

1 reference

3 August 2017

volume

2

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

443-451

1 reference

Genital herpes and public health: addressing a global problem

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Herpes simplex virus type 2 in the United States, 1976 to 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Risk Factors for the Sexual Transmission of Genital Herpes

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Current recommendations for the treatment of genital herpes.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Imiquimod applied topically: a novel immune response modifier and new class of drug

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Cytokine induction by the immunomodulators imiquimod and S-27609

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Imiquimod 5% cream in the treatment of Bowen's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Imiquimod: a novel treatment for lentigo maligna

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

The immune response modifier resiquimod mimics CD40-induced B cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Immunomodulating and antiviral activities of the imidazoquinoline S-28463.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

CD28/B7 system of T cell costimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Production of interferon-alpha/beta by murine dendritic cell lines stimulated by virus and bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Imiquimod, a topical immune response modifier, induces migration of Langerhans cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Prospects for control of herpes simplex virus disease through immunization.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2801%2900184-9

7 January 2021

10.1016/S1567-5769(01)00184-9

Identifiers

DOI

1 reference

3 August 2017

1 reference